Co-developed by ABL Bio and Novabridge
Simultaneous Targeting of Claudin 18.2 and 4-1BB

ABL Bio announced on February 17 (local time) that it has begun dosing the first patient in a global Phase 2 clinical trial of the combination therapy of ABL111 (Givastomig), which is being co-developed with its U.S. partner Novabridge Biosciences.


This Phase 2 trial is designed to evaluate the potential of the combination therapy of ABL111, the programmed cell death protein 1 (PD-1) inhibitor nivolumab, and the chemotherapy regimen mFOLFOX6 as a first-line treatment for patients with metastatic gastric cancer. The two companies plan to assess approximately 180 patients who are positive for Claudin 18.2 and PD-L1.

ABL111 Combination Therapy Enters Global Phase 2...Evaluating First-Line Treatment for Metastatic Gastric Cancer View original image

ABL111 is a bispecific antibody that simultaneously targets Claudin 18.2 and 4-1BB, and is one of the pipelines developed on the 4-1BB-based bispecific antibody platform Grabody-T. Claudin 18.2 is a protein expressed in gastric mucosal epithelial cells that becomes overexpressed on the cell surface when cancer develops and is utilized as an anticancer target. 4-1BB is a receptor expressed on the surface of immune cells such as T cells, and when activated, it amplifies antitumor immune responses.


In a prior Phase 1b trial, the objective response rate (ORR) of the ABL111 combination therapy at 8 mg/kg was 77%, and the ORR at 12 mg/kg was 73% (19/26). ABL Bio explained, "Consistent responses were observed regardless of the patients' PD-L1 and Claudin 18.2 expression levels," adding, "The safety profile was also similar to that of the current first-line standard of care, demonstrating overall favorable tolerability."


Lee Sanghoon, CEO of ABL Bio, said, "Since ABL111 demonstrated best-in-class potential in the Phase 1b trial, we expect to see strong results in this Phase 2 study as well."



Philippe Denis, Chief Medical Officer (CMO) of Novabridge, said, "This study was designed to validate data in a broader patient population, ranging from PD-L1-positive patients to Claudin 18.2-positive patients," adding, "We expect to announce the top-line results of the Phase 2 trial in 2027, and the Phase 1b data are scheduled to be released in the second half of this year."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing